VCU School of Pharmacy alumna Kellie Schoolar Reynolds (Pharm.D. ’92) will be inducted as president of the American Society for Clinical Pharmacology and Therapeutics during its 2017 Annual Meeting March 15-18 in Washington.
ASCPT notes that as deputy director of the Division of Clinical Pharmacology IV at the Food and Drug Administration’s Center for Drug Evaluation and Research, Reynolds plays a leading role in the development and regulatory review of anti-infectives, antivirals, immunosuppressants and ophthalmology drug products as well as counterterrorism drug products. She has long studied the pharmacokinetics and pharmacodynamics of these treatments and their potential for drug interactions.
Reynolds has been with the FDA since 1994. At CDER, she works with the Renal Impairment Working Group, the Antibiotic Drug Development Task Force and the Drug Interaction Working Group. Her research and practical guidance on the management of drug interactions has been published in various peer-reviewed journals and books, and she has made more than 30 presentations at professional meetings. She has worked closely with undergraduate pharmacy students and fellows, particularly in the areas of career development and transition.
An ASCPT member for eight years, she was appointed to its board of directors in 2014. She has been involved in numerous society activities, including its By-Laws Committee, Strategic Planning Task Force, Clinical and Translational Science Steering and Search Committee and Mentoring Task Force. She also has chaired the Drug Development and Regulatory Scientific Section and Scientific Program Committee.
She served as an associate editor for Clinical Pharmacology & Therapeutics for six years and was an editorial board member.
Reynolds earned her bachelor’s degree in biochemistry at Virginia Tech. Following graduation from VCU School of Pharmacy, she completed a clinical pharmacokinetics and drug development fellowship at University of North Carolina at Chapel Hill.
Established in 1900, ASCPT now has more than 2,200 members committed to advancing the science and practice of translational medicine, building on a foundation of clinical pharmacology and therapeutics.